Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
VEZEAU, ET AL v. PFIZER, INC.
Case Number:
2:05-cv-06795
Court:
Nature of Suit:
Other Statutes: Other Statutory Actions
Judge:
Firms
- Armstrong Teasdale
- DLA Piper
- Duane Morris
- Florio Perrucci
- Kirby McInerney
- Milberg Coleman
- Morgan Verkamp
- Ropes & Gray
- Sanford Heisler
Companies
Sectors & Industries:
-
June 22, 2017
Pfizer Wins Interlocutory Review In Vfend Whistleblower Suit
A Pennsylvania federal judge agreed Thursday to allow the Third Circuit to weigh in on whether he should have granted a motion from Pfizer Inc. to throw out a whistleblower suit accusing the company of pushing illegal off-label use of its antifungal medication Vfend.
-
April 12, 2017
Pfizer Can't Shake Off-Label Marketing FCA Suit
A Pennsylvania federal judge on Wednesday denied Pfizer Inc.'s bid to dismiss a False Claims Act suit alleging the company pushed illegal off-label use of its anti-fungal medication Vfend, ruling the suit was not filed too late.
-
March 02, 2016
Pfizer Can't Escape Narrowed Off-Label Marketing FCA Suit
A Pennsylvania federal judge on Monday trimmed a False Claims Act suit against Pfizer Inc., but left room for the whistleblowers to refile and pursue other claims alleging illegal off-label marketing and kickback practices relating to the drugmaker's anti-fungal medication Vfend.
-
November 29, 2011
Unsealed FCA Suit Accuses Pfizer Of Off-Label Marketing
A federal court on Tuesday unsealed two ex-Pfizer Inc. employees' qui tam suit alleging the drugmaker marketed anti-fungal medication Vfend for off-label use that put patients at risk and caused the submission of millions of dollars in claims to government programs in violation of the False Claims Act.